INFO & CONTACTS:  +39 02 2390 1

Phase II study of lurbinectedin and irinotecan in adult and young adult patients with advanced desmoplastic small round cell tumor (DSRCT).

Phase: Phase II-III clinical trials

Principal Investigator: Dott.ssa Stacchiotti Silvia

Main Facility: Oncologia Medica 2

Drug: Lurbinectedina e Irinotecan

Pathologies: Other

ClinicalTrials.gov: Read more about clinical trials

This clinical study is a multicenter, prospective, phase II, single-arm, open-label study, sponsored by the Italian Sarcoma Group (ISG) and the Spanish Sarcoma Group (GEIS), aimed at evaluating the activity of the combination of lurbinectedin and irinotecan in patients aged ≥15 years affected by desmoplastic small round cell tumor (DSRCT) with EWSR1-WT1 translocation, in an advanced stage (locally advanced or metastatic) of disease, progressing after anthracycline-based chemotherapy, from the second to the fourth line of treatment. 

Patients enrolled in the study will receive the experimental combination of lurbinectedin and irinotecan and will undergo periodic clinical and radiological assessments to evaluate treatment activity and monitor safety. Treatment will be continued until disease progression, unacceptable toxicity, Patient’s choice, or clinical decision. 

The study also includes a translational research program aimed at characterizing the genomic and transcriptomic profile of the disease. Tumor samples and peripheral blood samples will be collected at different timepoints during the study in order to further investigate the biological mechanisms of the disease and identify potential predictive biomarkers.

Last update: 21/04/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe